Swiss National Bank Decreases Stock Position in Haemonetics Corporation $HAE

Swiss National Bank trimmed its position in shares of Haemonetics Corporation (NYSE:HAE) by 1.4% in the second quarter, Holdings Channel.com reports. The firm owned 95,900 shares of the medical instruments supplier’s stock after selling 1,400 shares during the period. Swiss National Bank’s holdings in Haemonetics were worth $7,155,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in HAE. Geode Capital Management LLC grew its stake in shares of Haemonetics by 1.9% during the second quarter. Geode Capital Management LLC now owns 1,244,624 shares of the medical instruments supplier’s stock valued at $92,873,000 after acquiring an additional 23,257 shares in the last quarter. Royal Bank of Canada grew its stake in Haemonetics by 2.3% during the 1st quarter. Royal Bank of Canada now owns 1,075,604 shares of the medical instruments supplier’s stock valued at $68,355,000 after purchasing an additional 24,650 shares in the last quarter. SG Capital Management LLC increased its holdings in Haemonetics by 92.5% during the 2nd quarter. SG Capital Management LLC now owns 906,892 shares of the medical instruments supplier’s stock worth $67,663,000 after purchasing an additional 435,660 shares during the last quarter. Citigroup Inc. increased its holdings in Haemonetics by 87.3% during the 1st quarter. Citigroup Inc. now owns 625,565 shares of the medical instruments supplier’s stock worth $39,755,000 after purchasing an additional 291,574 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. raised its position in shares of Haemonetics by 0.9% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 556,027 shares of the medical instruments supplier’s stock valued at $35,336,000 after purchasing an additional 4,834 shares in the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.

Haemonetics Stock Performance

Shares of NYSE HAE opened at $81.35 on Monday. The company has a quick ratio of 1.04, a current ratio of 1.72 and a debt-to-equity ratio of 1.04. The firm’s 50-day moving average price is $58.57 and its two-hundred day moving average price is $63.31. Haemonetics Corporation has a 52-week low of $47.31 and a 52-week high of $88.86. The stock has a market capitalization of $3.81 billion, a P/E ratio of 24.88, a P/E/G ratio of 0.91 and a beta of 0.43.

Haemonetics (NYSE:HAE) last announced its quarterly earnings results on Thursday, November 6th. The medical instruments supplier reported $1.27 earnings per share for the quarter, topping analysts’ consensus estimates of $1.12 by $0.15. The business had revenue of $327.32 million for the quarter, compared to analysts’ expectations of $311.61 million. Haemonetics had a return on equity of 26.64% and a net margin of 12.14%.The business’s quarterly revenue was down 5.3% on a year-over-year basis. During the same period in the prior year, the firm earned $1.12 EPS. Haemonetics has set its FY 2026 guidance at 4.800-5.00 EPS. As a group, sell-side analysts forecast that Haemonetics Corporation will post 4.55 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts have recently weighed in on HAE shares. Citigroup decreased their price target on shares of Haemonetics from $78.00 to $64.00 and set a “buy” rating for the company in a research report on Tuesday, October 7th. BTIG Research reissued a “buy” rating and set a $88.00 price objective on shares of Haemonetics in a report on Friday, November 21st. JPMorgan Chase & Co. restated a “neutral” rating and issued a $62.00 target price (down previously from $85.00) on shares of Haemonetics in a research note on Friday, August 8th. Mizuho reduced their price target on shares of Haemonetics from $90.00 to $70.00 and set an “outperform” rating on the stock in a research report on Friday, August 8th. Finally, Needham & Company LLC boosted their price objective on Haemonetics from $68.00 to $78.00 and gave the company a “buy” rating in a report on Friday, November 7th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Haemonetics has a consensus rating of “Moderate Buy” and an average price target of $79.70.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.